热门资讯> 正文

ImmunityBio 2026年第四季度盈利预览

2026-03-03 06:38

ImmunityBio Inc(IBRX) 0
Stride(LRN) 0

ImmunityBio (IBRX) is scheduled to announce Q4 earnings results on Tuesday, March 3rd, after market close.
The consensus EPS Estimate is -$0.08 and the consensus Revenue Estimate is $44.77M (+521.8% Y/Y).
Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

More on ImmunityBio

ImmunityBio: Disconnect Between Clinical Progress And Stock Performance
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade)
Top 10 Healthcare Stocks of February
ImmunityBio forms Irish unit, distribution deal to improve Anktiva access in Europe

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。